image
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 2.05
-5.96 %
$ 146 M
Market Cap
-4.36
P/E
1. INTRINSIC VALUE

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer.[ Read More ]

The intrinsic value of one ACRS stock under the base case scenario is HIDDEN Compared to the current market price of 2.05 USD, Aclaris Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ACRS

image
FINANCIALS
31.2 M REVENUE
5.03%
-97.4 M OPERATING INCOME
-14.33%
-88.5 M NET INCOME
-1.81%
-78.3 M OPERATING CASH FLOW
-15.92%
46.2 M INVESTING CASH FLOW
266.01%
26.7 M FINANCING CASH FLOW
-63.35%
4.35 M REVENUE
57.12%
-10.5 M OPERATING INCOME
16.59%
-7.59 M NET INCOME
30.95%
22 M OPERATING CASH FLOW
278.54%
2.8 M INVESTING CASH FLOW
514.69%
22 K FINANCING CASH FLOW
300.00%
Balance Sheet Decomposition Aclaris Therapeutics, Inc.
image
Current Assets 129 M
Cash & Short-Term Investments 119 M
Receivables 298 K
Other Current Assets 9.45 M
Non-Current Assets 68.5 M
Long-Term Investments 62.8 M
PP&E 1.62 M
Other Non-Current Assets 4.16 M
Current Liabilities 31 M
Accounts Payable 8.88 M
Short-Term Debt 852 K
Other Current Liabilities 21.2 M
Non-Current Liabilities 9.27 M
Long-Term Debt 0
Other Non-Current Liabilities 9.27 M
EFFICIENCY
Earnings Waterfall Aclaris Therapeutics, Inc.
image
Revenue 31.2 M
Cost Of Revenue 18.1 M
Gross Profit 13.2 M
Operating Expenses 111 M
Operating Income -97.4 M
Other Expenses -8.88 M
Net Income -88.5 M
RATIOS
42.14% GROSS MARGIN
42.14%
-311.55% OPERATING MARGIN
-311.55%
-283.15% NET MARGIN
-283.15%
-56.29% ROE
-56.29%
-44.82% ROA
-44.82%
-61.52% ROIC
-61.52%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Aclaris Therapeutics, Inc.
image
Net Income -88.5 M
Depreciation & Amortization 863 K
Capital Expenditures -1.31 M
Stock-Based Compensation 20.5 M
Change in Working Capital 9.39 M
Others -9.6 M
Free Cash Flow -79.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Aclaris Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for ACRS of $3 , with forecasts ranging from a low of $3 to a high of $3 .
ACRS Lowest Price Target Wall Street Target
3 USD 46.34%
ACRS Average Price Target Wall Street Target
3 USD 46.34%
ACRS Highest Price Target Wall Street Target
3 USD 46.34%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Aclaris Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
5.59 M USD 1
3-6 MONTHS
18 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
3 months ago
Aug 05, 2024
Bought 256 K USD
Leonard Braden Michael
10 percent owner
+ 206025
1.2443 USD
3 months ago
Aug 02, 2024
Bought 216 K USD
Leonard Braden Michael
10 percent owner
+ 167544
1.2916 USD
3 months ago
Jul 31, 2024
Bought 133 K USD
Leonard Braden Michael
10 percent owner
+ 100000
1.3264 USD
3 months ago
Jul 30, 2024
Bought 226 K USD
Leonard Braden Michael
10 percent owner
+ 173730
1.303 USD
3 months ago
Jul 22, 2024
Bought 23.6 K USD
Leonard Braden Michael
10 percent owner
+ 17716
1.3297 USD
3 months ago
Jul 19, 2024
Bought 8.7 K USD
Leonard Braden Michael
10 percent owner
+ 6689
1.3 USD
4 months ago
Jul 18, 2024
Bought 170 K USD
Leonard Braden Michael
10 percent owner
+ 130317
1.3011 USD
4 months ago
Jul 05, 2024
Bought 141 K USD
Leonard Braden Michael
10 percent owner
+ 123017
1.1489 USD
4 months ago
Jul 03, 2024
Bought 166 K USD
Leonard Braden Michael
10 percent owner
+ 143288
1.159 USD
4 months ago
Jul 02, 2024
Bought 98.5 K USD
Leonard Braden Michael
10 percent owner
+ 86092
1.144 USD
4 months ago
Jul 01, 2024
Bought 122 K USD
Leonard Braden Michael
10 percent owner
+ 107434
1.1373 USD
4 months ago
Jun 28, 2024
Bought 452 K USD
Leonard Braden Michael
10 percent owner
+ 400000
1.13 USD
4 months ago
Jun 28, 2024
Bought 897 K USD
Leonard Braden Michael
10 percent owner
+ 801000
1.1193 USD
4 months ago
Jun 27, 2024
Bought 271 K USD
Leonard Braden Michael
10 percent owner
+ 235000
1.1546 USD
5 months ago
Jun 18, 2024
Bought 56.5 K USD
Leonard Braden Michael
10 percent owner
+ 50000
1.1301 USD
5 months ago
Jun 17, 2024
Bought 169 K USD
Leonard Braden Michael
10 percent owner
+ 150000
1.13 USD
5 months ago
Jun 14, 2024
Bought 402 K USD
Leonard Braden Michael
10 percent owner
+ 345000
1.1658 USD
5 months ago
Jun 13, 2024
Bought 575 K USD
Leonard Braden Michael
10 percent owner
+ 500000
1.15 USD
5 months ago
Jun 13, 2024
Bought 32.8 K USD
Leonard Braden Michael
10 percent owner
+ 28621
1.1445 USD
5 months ago
Jun 12, 2024
Bought 94.1 K USD
Leonard Braden Michael
10 percent owner
+ 82579
1.14 USD
5 months ago
Jun 11, 2024
Bought 1.08 M USD
Leonard Braden Michael
10 percent owner
+ 1000000
1.08 USD
8 months ago
Mar 04, 2024
Bought 7.5 K USD
Powell Andrew Kenneth William
Director
+ 6000
1.25 USD
8 months ago
Mar 01, 2024
Bought 10.5 K USD
Powell Andrew Kenneth William
Director
+ 8500
1.23 USD
1 year ago
Oct 23, 2023
Sell 30.5 K USD
Monahan Joseph
Chief Scientific Officer
- 6000
5.0767 USD
1 year ago
Sep 06, 2023
Bought 75 K USD
Balthaser Kevin
Chief Financial Officer
+ 9490
7.9 USD
1 year ago
Aug 28, 2023
Bought 100 K USD
Loerop James
Chief Business Officer
+ 14705
6.7976 USD
1 year ago
Aug 21, 2023
Sell 43.9 K USD
Monahan Joseph
Chief Scientific Officer
- 6000
7.3158 USD
1 year ago
Jun 20, 2023
Sell 61.7 K USD
Monahan Joseph
Chief Scientific Officer
- 6000
10.2771 USD
1 year ago
Mar 17, 2023
Bought 49.5 K USD
Manion Douglas J.
Pres and CEO
+ 6300
7.8623 USD
1 year ago
Mar 09, 2023
Bought 50.3 K USD
Manion Douglas J.
Pres and CEO
+ 6500
7.735 USD
1 year ago
Mar 02, 2023
Sell 359 K USD
Walker Neal
Director
- 29000
12.3651 USD
1 year ago
Mar 03, 2023
Sell 382 K USD
Walker Neal
Director
- 30240
12.6346 USD
1 year ago
Mar 02, 2023
Sell 183 K USD
Monahan Joseph
Chief Scientific Officer
- 14800
12.3665 USD
1 year ago
Mar 03, 2023
Sell 203 K USD
Monahan Joseph
Chief Scientific Officer
- 16037
12.6342 USD
1 year ago
Mar 03, 2023
Sell 11.3 K USD
Balthaser Kevin
Chief Financial Officer
- 894
12.6281 USD
1 year ago
Mar 02, 2023
Sell 12.3 K USD
Balthaser Kevin
Chief Financial Officer
- 1000
12.289 USD
1 year ago
Feb 15, 2023
Sell 65.3 K USD
Monahan Joseph
Chief Scientific Officer
- 5000
13.0621 USD
1 year ago
Feb 08, 2023
Sell 59.3 K USD
Loerop James
Chief Business Officer
- 4267
13.8909 USD
1 year ago
Feb 01, 2023
Sell 419 K USD
Walker Neal
Director
- 25000
16.747 USD
1 year ago
Feb 02, 2023
Sell 15.7 K USD
Walker Neal
Director
- 1079
14.5671 USD
1 year ago
Feb 02, 2023
Sell 9.33 K USD
Walker Neal
Director
- 600
15.5533 USD
1 year ago
Feb 02, 2023
Sell 52.7 K USD
Walker Neal
Director
- 3121
16.8827 USD
1 year ago
Feb 02, 2023
Sell 3.51 K USD
Walker Neal
Director
- 200
17.535 USD
1 year ago
Jan 03, 2023
Sell 355 K USD
Walker Neal
Director
- 23382
15.1855 USD
1 year ago
Jan 03, 2023
Sell 26.1 K USD
Walker Neal
Director
- 1618
16.1594 USD
1 year ago
Jan 04, 2023
Sell 223 K USD
Walker Neal
Director
- 15000
14.8895 USD
1 year ago
Dec 15, 2022
Sell 79.4 K USD
Monahan Joseph
Chief Scientific Officer
- 5000
15.8823 USD
2 years ago
Nov 10, 2022
Sell 194 K USD
SCHIFF ANDREW N
Director
- 11395
17.0246 USD
2 years ago
Nov 11, 2022
Sell 702 K USD
SCHIFF ANDREW N
Director
- 41160
17.0597 USD
2 years ago
Nov 14, 2022
Sell 23.4 K USD
SCHIFF ANDREW N
Director
- 1371
17.08 USD
2 years ago
Oct 24, 2022
Sell 249 K USD
SCHIFF ANDREW N
Director
- 14616
17.0078 USD
2 years ago
Oct 25, 2022
Sell 205 K USD
SCHIFF ANDREW N
Director
- 12018
17.0175 USD
2 years ago
Oct 26, 2022
Sell 247 K USD
SCHIFF ANDREW N
Director
- 14540
17.005 USD
2 years ago
Oct 17, 2022
Sell 320 K USD
SCHIFF ANDREW N
Director
- 19944
16.0493 USD
2 years ago
Oct 18, 2022
Sell 542 K USD
SCHIFF ANDREW N
Director
- 32093
16.8891 USD
2 years ago
Oct 17, 2022
Sell 79.9 K USD
Monahan Joseph
Chief Scientific Officer
- 5000
15.9815 USD
2 years ago
Oct 07, 2022
Sell 118 K USD
SCHIFF ANDREW N
Director
- 7324
16.1591 USD
2 years ago
Oct 04, 2022
Sell 123 K USD
SCHIFF ANDREW N
Director
- 7700
16.0076 USD
2 years ago
Oct 06, 2022
Sell 626 K USD
SCHIFF ANDREW N
Director
- 37839
16.537 USD
2 years ago
Jun 17, 2022
Sell 296 K USD
SCHIFF ANDREW N
director:
- 19565
15.1428 USD
2 years ago
Apr 21, 2022
Sell 381 K USD
Walker Neal
President and CEO
- 25000
15.2379 USD
2 years ago
Apr 21, 2022
Sell 376 K USD
Walker Neal
President and CEO
- 25000
15.0439 USD
2 years ago
Apr 25, 2022
Sell 304 K USD
Walker Neal
President and CEO
- 20000
15.1828 USD
2 years ago
Apr 18, 2022
Sell 488 K USD
Monahan Joseph
Chief Scientific Officer
- 30000
16.2766 USD
2 years ago
Mar 11, 2022
Sell 896 K USD
Walker Neal
President and CEO
- 56303
15.9147 USD
2 years ago
Mar 10, 2022
Sell 199 K USD
Ruffo Frank
Chief Financial Officer
- 12823
15.5451 USD
2 years ago
Mar 10, 2022
Sell 427 K USD
Monahan Joseph
Chief Scientific Officer
- 27165
15.7115 USD
2 years ago
Feb 09, 2022
Sell 4.86 K USD
Monahan Joseph
Chief Scientific Officer
- 383
12.6818 USD
2 years ago
Feb 09, 2022
Sell 17.6 K USD
Ruffo Frank
Chief Financial Officer
- 1388
12.6574 USD
2 years ago
Feb 09, 2022
Sell 45.5 K USD
Walker Neal
President and CEO
- 3595
12.6602 USD
3 years ago
Jul 13, 2021
Sell 44.7 K USD
Gordon David N.
Chief Medical Officer
- 2631
16.9801 USD
3 years ago
Jun 03, 2021
Sell 208 K USD
Ali-Jackson Kamil
Chief Legal Officer
- 9492
21.9575 USD
3 years ago
Jun 01, 2021
Sell 207 K USD
Gordon David N.
Chief Medical Officer
- 9115
22.7124 USD
3 years ago
Jun 01, 2021
Sell 115 K USD
Gordon David N.
Chief Medical Officer
- 4885
23.5705 USD
3 years ago
Jun 02, 2021
Sell 669 K USD
Gordon David N.
Chief Medical Officer
- 31114
21.4954 USD
3 years ago
Jun 02, 2021
Sell 151 K USD
Gordon David N.
Chief Medical Officer
- 6800
22.2649 USD
3 years ago
Jun 01, 2021
Sell 221 K USD
Ali-Jackson Kamil
Chief Legal Officer
- 9746
22.7219 USD
3 years ago
Jun 01, 2021
Sell 124 K USD
Ali-Jackson Kamil
Chief Legal Officer
- 5254
23.5728 USD
3 years ago
Jun 02, 2021
Sell 268 K USD
Ali-Jackson Kamil
Chief Legal Officer
- 12483
21.5022 USD
3 years ago
Jun 02, 2021
Sell 56.2 K USD
Ali-Jackson Kamil
Chief Legal Officer
- 2517
22.3175 USD
3 years ago
Jun 02, 2021
Sell 274 K USD
Ali-Jackson Kamil
Chief Legal Officer
- 12732
21.5066 USD
3 years ago
Jun 02, 2021
Sell 53.3 K USD
Ali-Jackson Kamil
Chief Legal Officer
- 2387
22.3112 USD
3 years ago
Jun 02, 2021
Sell 392 K USD
Monahan Joseph
Chief Scientific Officer
- 18240
21.5039 USD
3 years ago
Jun 02, 2021
Sell 79.2 K USD
Monahan Joseph
Chief Scientific Officer
- 3550
22.3114 USD
3 years ago
Jun 02, 2021
Sell 271 K USD
Ruffo Frank
Chief Financial Officer
- 12587
21.5101 USD
3 years ago
Jun 02, 2021
Sell 54.6 K USD
Ruffo Frank
Chief Financial Officer
- 2450
22.3 USD
3 years ago
Jun 02, 2021
Sell 597 K USD
Walker Neal
President and CEO
- 27743
21.508 USD
3 years ago
Jun 02, 2021
Sell 123 K USD
Walker Neal
President and CEO
- 5517
22.3017 USD
3 years ago
May 06, 2021
Sell 277 K USD
Ali-Jackson Kamil
Chief Legal Officer
- 11898
23.318 USD
3 years ago
May 07, 2021
Sell 77 K USD
Ali-Jackson Kamil
Chief Legal Officer
- 3316
23.2255 USD
3 years ago
May 06, 2021
Sell 74 K USD
Ali-Jackson Kamil
Chief Legal Officer
- 3102
23.8606 USD
3 years ago
May 07, 2021
Sell 50.4 K USD
Ali-Jackson Kamil
Chief Legal Officer
- 2100
23.9886 USD
3 years ago
May 03, 2021
Sell 261 K USD
Ali-Jackson Kamil
Chief Legal Officer
- 10661
24.4578 USD
3 years ago
May 04, 2021
Sell 324 K USD
Ali-Jackson Kamil
Chief Legal Officer
- 13721
23.6055 USD
3 years ago
May 05, 2021
Sell 348 K USD
Ali-Jackson Kamil
Chief Legal Officer
- 14502
23.968 USD
3 years ago
May 04, 2021
Sell 31.3 K USD
Ali-Jackson Kamil
Chief Legal Officer
- 1279
24.4691 USD
3 years ago
May 03, 2021
Sell 108 K USD
Ali-Jackson Kamil
Chief Legal Officer
- 4339
24.9075 USD
3 years ago
May 05, 2021
Sell 12.1 K USD
Ali-Jackson Kamil
Chief Legal Officer
- 498
24.3559 USD
3 years ago
Apr 22, 2021
Sell 805 K USD
Ruffo Frank
Chief Financial Officer
- 30000
26.8406 USD
3 years ago
Apr 23, 2021
Sell 778 K USD
Ruffo Frank
Chief Financial Officer
- 29200
26.6369 USD
3 years ago
Apr 23, 2021
Sell 21.9 K USD
Ruffo Frank
Chief Financial Officer
- 800
27.3287 USD
3 years ago
Apr 26, 2021
Sell 703 K USD
Ruffo Frank
Chief Financial Officer
- 27239
25.7933 USD
3 years ago
Apr 26, 2021
Sell 2.64 K USD
Ruffo Frank
Chief Financial Officer
- 100
26.44 USD
3 years ago
Apr 22, 2021
Sell 805 K USD
Walker Neal
President and CEO
- 30000
26.8413 USD
7. News
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.41 per share a year ago. zacks.com - 1 week ago
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Trea globenewswire.com - 2 months ago
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference WAYNE, Pa., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024 at 8:00 AM ET in New York, New York. globenewswire.com - 2 months ago
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.42 per share a year ago. zacks.com - 3 months ago
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year? Here is how Aclaris Therapeutics (ACRS) and Adma Biologics (ADMA) have performed compared to their sector so far this year. zacks.com - 3 months ago
AllClear Repair Services Approved as Honeywell Authorized Service Center MIRAMAR, Fla.--(BUSINESS WIRE)-- #defenseaerospace--AllClear Repair Services (“ACRS”), a wholly owned subsidiary of AllClear Aerospace & Defense (“AllClear”), has been approved by Honeywell as an authorized service center for Honeywell military APUs and mechanical components for C-130, F-15, F-16, F-18 and military derivatives of B707 platforms. The Honeywell authorized service center agreement authorizes ACRS to perform maintenance on pneumatic components, starter control valves, anti-ice valves, wheels and b. businesswire.com - 3 months ago
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million - Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities - - $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the sale of a portion of Aclaris' future royalty payments and certain milestones from Eli Lilly and Company (Lilly) on net sales of OLUMIANT® (baricitinib) for the treatment of alopecia areata to OMERS, one of Canada's largest defined benefit pension plans. globenewswire.com - 4 months ago
3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices Trading volume spikes in beaten-down stocks often signal a bottom for prices investors can bank on. The problem is that beaten-down stocks are usually in that position for a good reason, so it helps if there is a catalyst for higher share prices in addition to the trading volume. marketbeat.com - 4 months ago
Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte) Dublin, June 25, 2024 (GLOBE NEWSWIRE) -- The "Rheumatoid Arthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been added to ResearchAndMarkets.com's offering. The 7 major rheumatoid arthritis markets reached a value of US$ 27.5 billion in 2023. Looking forward, the 7MM are projected to reach US$ 33.8 billion by 2034, exhibiting a growth rate (CAGR) of 2.32% during 2023-2034. globenewswire.com - 4 months ago
Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will participate in a fireside chat during the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 11:20 AM ET in Miami, Florida. A webcast of the fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris' website, www.aclaristx.com. globenewswire.com - 5 months ago
American Clinical Research Services Announces Strategic Acquisition of Elixia RALEIGH, N.C.--(BUSINESS WIRE)--American Clinical Research Services Announces Strategic Acquisition of Elixia. businesswire.com - 6 months ago
Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript Aclaris Therapeutics, Inc. (NASDAQ:ACRS ) Q1 2024 Results Conference Call May 7, 2024 5:00 PM ET Company Participants Kevin Balthaser - Chief Financial Officer Neal Walker - Interim Chief Executive Officer Joe Monahan - Chief Scientific Officer Wally Smith - Scientific & Business Development Consultant Conference Call Participants Roger Song - Jefferies Thomas Smith - Leerink Partners Corinne Jenkins - Goldman Sachs Julian Harrison - Big TIG Alex Thompson - Stifel Gavin Clark-Gartner - Evercore ISI Operator Good day, and thank you for standing by. Welcome to the Aclaris Therapeutics First Quarter 2024 Conference Call. seekingalpha.com - 6 months ago
8. Profile Summary

Aclaris Therapeutics, Inc. ACRS

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 146 M
Dividend Yield 0.00%
Description Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Contact 640 Lee Road, Wayne, PA, 19087 https://www.aclaristx.com
IPO Date Oct. 6, 2015
Employees 86
Officers Mr. Steve Tucker Senior Vice President of Project Leadership Dr. Jon Jacobsen Ph.D. Senior Vice President of Chemistry Dr. Neal S. Walker D.O., M.D. Co-Founder, President, Chairman & Interim Chief Executive Officer Mr. Kevin Balthaser Chief Financial Officer Dr. Joseph Monahan Ph.D. Chief Scientific Officer Mr. James Loerop Chief Business Officer Mr. Matthew Rothman J.D. General Counsel & Corporate Secretary Mr. Ajay Aggarwal M.B.A., M.D. Senior Vice President of Clinical Development